IL15 and lymphoid leukemia: For example, transgenes comprising a non-cleavable, high-affinity CD16 and an interleukin-15 fusion protein has been used to augment the survival and function of FT596, the first ever iPSC-derived NK cells targeting CD19-positive lymphoid leukemias underwent a clinical trial (NCT04245722) [41].